Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2001-2-22
pubmed:abstractText
To evaluate the safety of BufferGel (ReProtect LLC, Baltimore, MD), a spermicidal microbicide that acidifies semen and maintains the protective acidity of the vagina, in a high-dose tolerance trial.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1525-4135
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
21-7
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:11176265-Acrylic Resins, pubmed-meshheading:11176265-Administration, Intravaginal, pubmed-meshheading:11176265-Adult, pubmed-meshheading:11176265-Anti-Infective Agents, Local, pubmed-meshheading:11176265-Cohort Studies, pubmed-meshheading:11176265-Coitus, pubmed-meshheading:11176265-Female, pubmed-meshheading:11176265-HIV Infections, pubmed-meshheading:11176265-Humans, pubmed-meshheading:11176265-Hydrogen-Ion Concentration, pubmed-meshheading:11176265-India, pubmed-meshheading:11176265-Malawi, pubmed-meshheading:11176265-Sexual Abstinence, pubmed-meshheading:11176265-Spermatocidal Agents, pubmed-meshheading:11176265-Thailand, pubmed-meshheading:11176265-Vagina, pubmed-meshheading:11176265-Vaginosis, Bacterial, pubmed-meshheading:11176265-Yeasts, pubmed-meshheading:11176265-Zimbabwe
pubmed:year
2001
pubmed:articleTitle
Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites.
pubmed:affiliation
University of Zimbabwe-University of California San Francisco Women's Health Program, Harare, Zimbabwe. jvandewijgert@popcouncil.org
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase I